When a family is staring down an Alzheimer’s diagnosis, the question of memantine vs donepezil comes up fast. Usually within the first week. The neurologist mentions one, or both, and the family goes home trying to figure out what they actually do and which one is going to help mom or dad the most.
The honest answer is that these two drugs aren’t really competitors. They work on completely different chemistry in the brain, and they’re often used at different stages of the disease. Sometimes together. That’s the part most articles skip over.
What follows is a plain comparison of how each drug works, who tends to benefit, and what to realistically expect. Both are FDA-approved for Alzheimer’s disease, and both have decades of real-world data behind them.
How Each Drug Actually Works
Donepezil (brand name Aricept) is a cholinesterase inhibitor. It blocks the enzyme that breaks down acetylcholine, a neurotransmitter that’s central to memory and attention. Alzheimer’s progressively destroys the neurons that make acetylcholine, so donepezil tries to preserve what’s left. Think of it as slowing the leak, not patching the hole.
Memantine (brand name Namenda) does something completely different. It’s an NMDA receptor antagonist. In Alzheimer’s, glutamate, another neurotransmitter, floods the brain at toxic levels and contributes to neuron death. Memantine dampens that overstimulation. It doesn’t boost memory chemistry the way donepezil does. It protects neurons from getting fried.
That mechanistic difference is the whole reason the memantine vs donepezil debate often ends with "use both."
Who Each Drug Is Approved For
This is where stage matters a lot.
Donepezil is approved for mild, moderate, and severe Alzheimer’s disease. It’s typically the first drug prescribed at diagnosis.
Memantine is FDA-approved only for moderate to severe Alzheimer’s. Using it in mild disease isn’t supported by strong evidence, and most insurers won’t cover it for early-stage patients. If your loved one was just diagnosed and the MMSE score is in the low 20s or higher, donepezil is almost always where treatment starts.
Once disease progresses, the calculus changes. Many neurologists add memantine on top of donepezil somewhere around the moderate stage. The combination is well-tolerated and has modest additive benefit in clinical trials.
What the Evidence Actually Shows
Neither drug stops Alzheimer’s. Both modestly slow symptom progression for a window of time, usually 6 to 12 months of meaningful benefit, though some patients respond longer.
For donepezil, Cochrane reviews have consistently shown small but real improvements in cognition and daily function compared with placebo across all disease stages. The effect is measurable but not dramatic. Families often describe it as "she seems a little more like herself" rather than a transformation.
For memantine, the evidence is similar in size but limited to moderate-to-severe disease. A landmark study published in the New England Journal of Medicine showed memantine slowed functional decline in patients with moderate-to-severe Alzheimer’s, and the benefit was independent of whether patients were also taking donepezil.
So in the memantine vs donepezil comparison, neither one "works better" in a head-to-head sense. They work on different problems, at different stages, and increasingly we treat them as partners rather than alternatives.
Side Effects: Where They Really Differ
This is often what decides which drug a patient can actually stay on.
Donepezil’s side effects come from boosting acetylcholine system-wide:
- Nausea, diarrhea, loss of appetite (often the dose-limiting issue)
- Vivid dreams or nightmares
- Muscle cramps
- Slow heart rate, sometimes clinically significant
- Weight loss
Patients who already struggle with reflux, bradycardia, or low body weight often have a rough time. We cover the full picture in this breakdown of donepezil side effects worth reading before starting.
Memantine is usually better tolerated. Common side effects include:
- Dizziness
- Headache
- Constipation
- Occasional confusion, especially during titration
It doesn’t typically cause the GI misery donepezil can. For patients who can’t tolerate cholinesterase inhibitors at all, memantine is sometimes used alone in moderate disease, even though that’s slightly off the standard sequencing.
If a patient is struggling with GI side effects specifically, the rivastigmine patch is often easier on the stomach than oral donepezil, which is worth raising with the prescriber. There’s also a useful comparison of galantamine and donepezil if cholinesterase inhibitor choice is on the table.
Cost and Practical Considerations
Both drugs are available as generics, which has made cost much less of a barrier than it was a decade ago. Generic donepezil typically runs under $15 a month at most US pharmacies. Generic memantine is similar, sometimes a bit higher depending on formulation (immediate-release vs extended-release).
Combination products containing both memantine and donepezil exist (Namzaric is the brand) but are significantly more expensive than taking the two generics separately. For most patients, separate generics make more financial sense. You can compare generic memantine and donepezil pricing at edrugstore.com to get a sense of what you’d actually pay out of pocket.
Dosing matters too. Donepezil is once daily, usually at bedtime. Memantine immediate-release is twice daily, while the extended-release version is once daily. For a caregiver managing multiple medications, that scheduling difference can matter more than people expect.
So Which One Is Better?
For early Alzheimer’s, donepezil is the answer. Memantine isn’t approved or particularly useful at that stage.
For moderate to severe Alzheimer’s, the better question isn’t memantine vs donepezil at all. It’s whether to use both. Combination therapy has the strongest evidence base for patients in that disease window, and it’s what most specialists default to when the disease progresses.
Your prescriber will weigh the patient’s stage, other medical conditions (especially heart rate, GI status, and kidney function), and tolerability. None of this is one-size-fits-all, and the right regimen often shifts as the disease evolves. Talk to your pharmacist or neurologist about whether the memantine vs donepezil decision in your situation should really be an "or" or an "and."
This article is for informational purposes only and is not medical advice. Always consult a licensed pharmacist or physician before starting, stopping, or changing any medication.
References
- FDA: Information on Alzheimer’s Drugs, official approval and labeling information for both drugs.
- MedlinePlus: Donepezil, NIH patient-facing summary of donepezil use and dosing.
- Cochrane Review: Donepezil for Dementia, systematic review of donepezil efficacy across disease stages.
- New England Journal of Medicine: Memantine in Moderate-to-Severe Alzheimer’s Disease, pivotal trial establishing memantine’s benefit in advanced disease.
Dr Steven Schlosser
Dr. Schlosser graduated from Lafayette College Phi Beta Kappa and attended Georgetown Medical School. He had 4 years of medical residency training at Tufts University in Boston in both Gynecology and Internal Medicine. He has had a spotless medical career for the past 40+ years and is Board Certified. Learn More